Investment analysts at StockNews.com started coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) in a research note issued on Friday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.
Titan Pharmaceuticals Price Performance
NASDAQ TTNP opened at $5.73 on Friday. The business has a fifty day simple moving average of $5.81 and a 200 day simple moving average of $6.59. Titan Pharmaceuticals has a 12 month low of $4.24 and a 12 month high of $14.80.
Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) last announced its earnings results on Thursday, August 15th. The specialty pharmaceutical company reported ($2.29) earnings per share (EPS) for the quarter.
About Titan Pharmaceuticals
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
Read More
- Five stocks we like better than Titan Pharmaceuticals
- Why is the Ex-Dividend Date Significant to Investors?
- Is Merck Stock Undervalued After Its Colossal Earnings Growth?
- With Risk Tolerance, One Size Does Not Fit All
- Top 5 ETFs for Every Investor: From Semiconductors to Defense
- Industrial Products Stocks Investing
- Blade Air Mobility: This Under-the-Radar Stock Could Double Soon
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
